Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
The online resource that help patients prescribed Entresto on their treatment journey
MyEntresto is designed to help:
- Boost understanding of heart failure
- Improve adherence to treatment 1
Whether you are prescribing ENTRESTO® (sacubitril/valsartan) for your eligible chronic HFrEF patients, or are supervising their ongoing treatment, ensuring adherence to their medication is critical. Lack of adherence could be because of many factors including in the patient’s symptoms, debilitating side effects or a busy lifestyle.
To support you in empowering your patients to stay on top of their condition and treatment, with the hope of improving adherence,Novartis has created and funded MyEntresto in partnership with HF patients: a patient portal dedicated to supporting the ENTRESTO community.
Designed to educate patients about their chronic heart failure/chronic HFrEF and explain how ENTRESTO works; by encouraging the use of the portal to your patients, you can improve their confidence and understanding around their treatment.
The MyEntresto portal forms a key part of our service to the wider ENTRESTO community, offering 24/7 patient support and resources.
Its key features include:
Mode of action video
A visual demonstration of how ENTRESTO works allowing patients better to understand the need for treatment.
Interactive 3D heart
Use this in patient consultations to explain how chronic HFrEF impacts the heart, and how your patient’s treatment will affect them.
Downloadable resources
Allowing your patients to understand their condition and treatment at their own pace.
Patient testimonials
Videos of real patients discussing their experience of diagnosis, symptoms and treatment.
Facts and statistics
Educational background information to help ensure your patient is well informed about both their condition and treatment.
Tips and advice
Lifestyle modification suggestions, appointment advice and guidance regarding their medication and side effects.
Taken together, the content of the MyEntresto portal aims to increase patient knowledge, breed confidence in their medication and deliver improved adherence. For HCPs, whether prescribers or those supporting patients on treatment, this may mean more meaningful appointments.
HCP, healthcare professional; HF, heart failure; HFrEF, heart failure with reduced ejection fraction.
References:
Aremu TO, et al. Pharmacy (Basel) 2022;10(5):106.
UK | June 2025 | FA-11326314
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.